These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 31021918)
1. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer. Beer L; Hochmair M; Haug AR; Schwabel B; Kifjak D; Wadsak W; Fuereder T; Fabikan H; Fazekas A; Schwab S; Mayerhoefer ME; Herold C; Prosch H Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918 [TBL] [Abstract][Full Text] [Related]
2. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466 [TBL] [Abstract][Full Text] [Related]
3. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods. Ayati N; Lee ST; Zakavi SR; Cheng M; Lau WFE; Parakh S; Pathmaraj K; Scott AM J Nucl Med; 2021 Jul; 62(7):926-933. PubMed ID: 33246978 [TBL] [Abstract][Full Text] [Related]
4. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781 [TBL] [Abstract][Full Text] [Related]
9. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy. Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356 [TBL] [Abstract][Full Text] [Related]
11. Comparison of RECIST and iRECIST criteria in patients with advanced lung cancer treated with nivolumab. Singla R; Jajodia A; Agrawal RK; Rao A; Pasricha S; Batra U J Cancer Res Ther; 2023; 19(5):1212-1218. PubMed ID: 37787285 [TBL] [Abstract][Full Text] [Related]
12. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275 [TBL] [Abstract][Full Text] [Related]
13. Response criteria in solid tumors (PERCIST/RECIST) and SUV Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779 [TBL] [Abstract][Full Text] [Related]
14. Comparison Between Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768 [TBL] [Abstract][Full Text] [Related]
15. The Value of Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398 [TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer. Kaira K; Yamaguchi O; Naruse I; Umeda Y; Honda T; Watanabe S; Ichikawa K; Yanagisawa S; Kasahara N; Higuchi T; Hashimoto K; Miura Y; Shiono A; Mouri A; Imai H; Iizuka K; Ishizuka T; Minato K; Suda S; Kagamu H; Mori K; Seki N; Kuji I Cancer Imaging; 2023 Mar; 23(1):23. PubMed ID: 36859341 [TBL] [Abstract][Full Text] [Related]
17. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Skougaard K; Nielsen D; Jensen BV; Hendel HW J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497 [TBL] [Abstract][Full Text] [Related]
18. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0. Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803 [TBL] [Abstract][Full Text] [Related]
19. The predictive value of Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034 [TBL] [Abstract][Full Text] [Related]
20. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]